Delivery Order SPE2DB22D3009-SPE2DB25FAZ63
- Not listed
- The Defense Logistics Agency awarded a $3,188.32 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials. This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 25, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials, valued at $6,376.64 with a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 13, 2025, and fulfillment is to occur at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 ml auto-injector vials with a ceiling value of $1,594.16. This delivery order, issued on June 20, 2025, with an ultimate completion date of July 14, 2025, operates under a firm fixed-price contract structure with no set-aside designation. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This award represents a continuation of...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Xolair 300 mg/2 mL auto-injector units. This non-set-aside, competitively awarded delivery order carries a ceiling value of $1,594.16 with firm fixed pricing and is scheduled for completion by August 7, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Xolair 300 mg/2 mL auto-injector units. This competitively awarded, non-set-aside contract has a ceiling value of $63,766.40 with a firm fixed price structure and an ultimate completion date of August 12, 2025. The place of performance is the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units valued at $1,594.16. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and no set-aside designation was applied. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a $6,376.64 delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 9, 2025, and performance to be completed at the vendor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,753.28 to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 mL auto-injectors. This firm fixed-price, non-set-aside contract is scheduled for completion by August 8, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Xolair 300 mg/2 ml auto-injector syringes valued at $1,594.16 with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's existing...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Xolair 300 mg/2 mL autoinjector units. This competitively awarded, firm fixed-price delivery order has a ceiling value of $6,376.64 and is scheduled for completion by August 12, 2025. The contract was performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FAZ63Delivery Order
The Defense Logistics Agency awarded a $6,376.64 delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, with an ultimate completion date of July 11, 2025, represents a non-competitive set-aside award and will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract falls under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that serves as the primary vehicle for supplying pharmaceutical products and medical commodities to military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, has demonstrated substantial capability in federal medical procurement through its extensive portfolio of competitively awarded contracts with the Defense Logistics Agency. The company supplies a comprehensive range of pharmaceutical products, medical devices, vaccines, and specialized healthcare commodities across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order exemplifies the company's role as a critical vendor within the federal medical supply chain, fulfilling specific pharmaceutical requirements on an as-needed basis under the umbrella of its substantial prime vendor agreement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.4k | 6/18/25 |